Day: March 4, 2017

Sanofi and Regeneron Announce Presentation of Positive Data from…

Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DupixentA in Moderate-to-Severe Atopic Dermatitis Sanofi and Regeneron Announce Presentation of Positive Data from Long-Term Pivotal Phase 3 CHRONOS Study of DupixentA in Moderate-to-Severe Atopic Dermatitis Paris, France and Tarrytown, N.Y. - March 4, 2017 - Sanofi and Regeneron Pharmaceuticals, Inc. today presented detailed results from the one-year Phase 3 CHRONOS study, which showed that patients receiving the investigational drug DupixentA with topical corticosteroids achieved significantly improved measures of overall disease severity compared to TCS alone in adults with uncontrolled moderate-to-severe atopic dermatitis .

Day In The Life: Knicks Physician Dr. Callahan

... a difference in whether somebody can play in the game. Let's say I walked in [to the Knicks' training facility in Tarrytown, N.Y.] this morning and there was a player who suddenly had a swollen knee. I'd could be getting the player an MRI. You ...